Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9678808 | 0.81 | CREBBP (0.56) | CREBBPNOS1KDM4EALDH1A1GRIN2D | |
| SCHEMBL23252425 | 0.81 | CREBBP (0.45) | CREBBPNOS1KDM4EALDH1A1GRIN2D | |
| SCHEMBL21460047 | 0.80 | NOS1 (0.56) | CREBBPNOS1KDM4EALDH1A1GRIN2D | |
| SCHEMBL31129257 | 0.79 | CREBBP (0.61) | CREBBPNOS1KDM4EALDH1A1GRIN2D | |
| SCHEMBL24430175 | 0.79 | CREBBP (0.52) | CREBBPNOS1KDM4EALDH1A1GRIN2D | |
| SCHEMBL4578890 | 0.78 | KDM4E (0.59) | KDM4EALDH1A1MAPKAPK2 | |
| SCHEMBL23252492 | 0.78 | CREBBP (0.44) | CREBBPNOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4576717 | 0.77 | GRIN2D (0.55) | CREBBPNOS1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL22425024 | 0.77 | NOS1 (0.60) | CREBBPNOS1MAPKAPK2POLBTDP1 | |
| SCHEMBL2590587 | 0.76 | CREBBP (0.61) | CREBBPNOS1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816376-B2 | Cyclic amides | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| EP-1485363-B1 | CYCLIC AMIDES | MERCK PATENT GMBH (DE) | 2008-10-08 | — | — | EP | disclosed |
| US-20050124627-A1 | Cyclic amides | MERCK PATENT GMBH (DE) | 2005-06-09 | — | — | US | disclosed |
| EP-1485363-A1 | CYCLIC AMIDES | MERCK PATENT GmbH (DE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076420-A1 | CYCLIC AMIDES | MERCK PATENT GMBH (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124627-A1 | Cyclic amides | NPY1R, GRIK1, GRIK4 | CREBBP 1702/4885NOS1 2666/4885KDM4E 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.